Effect of Goghrita And Shuktyadi Lepa in Crack Heels
Phase 3
Recruiting
- Conditions
- Health Condition 1: L989- Disorder of the skin and subcutaneous tissue, unspecified
- Registration Number
- CTRI/2019/05/019055
- Lead Sponsor
- Dr Ashish Zanwar
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Subjects having Sphutan with Ruja or Kandu will be selected
Exclusion Criteria
1 Known cases of Diabetes Mellitus, Plantar Keratoderma and Athleteâ??s Foot.
2 Subjects suffering from skin disorders like psoriasis, Hyperkeratotic eczema.
3 Subjects having excessive discharge from cracks of the heel.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method relife in symptomsTimepoint: at the end of the study
- Secondary Outcome Measures
Name Time Method comparison between both the drugs efficacy <br/ ><br>Timepoint: at the end of the study
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie the efficacy of Goghrita and Shuktyadi Lepa in treating crack heels?
How does the combination of Goghrita and Shuktyadi Lepa compare to standard-of-care treatments for Padadari (crack heels)?
Are there specific biomarkers that can predict patient response to Goghrita and Shuktyadi Lepa therapy for L989 skin disorders?
What are the potential adverse events associated with Goghrita and Shuktyadi Lepa in Phase III trials for crack heels management?
What related compounds or combination therapies show promise in managing disorders of the skin and subcutaneous tissue like L989?